DearMob

Deargen is an AI-first pharmatech company that integrates deep learning technology with biological data to accelerate the discovery and development of novel therapeutics. Based in South Korea, the company utilizes its proprietary platform, Dr. UG, to perform advanced genomic data analysis, biomarker prediction, and lead optimization for small molecule drugs. Deargen's internal pipeline focuses on high-unmet-need areas such as oncology, neurology, and rare diseases, with lead programs targeting conditions like DLBCL and triple-negative breast cancer. The company has established strategic collaborations with global pharmaceutical partners and academic institutions to validate its AI-driven candidates and streamline the early stages of R&D.